IP Library › Granted Patent US 12,246,042
Granted Patent B2
US 12,246,042 · App. 16/459,006 · Granted Mar 11, 2025

Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals

Inventors: Joseph Mannello (Cedar Knolls, NJ); Neerav Padliya (Cedar Knolls, NJ); Maghsoud Dariani (Cedar Knolls, NJ)
Assignee: MYOS CORP.
A61K35/57A61K38/1703A61P21/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,246,042
App. No.
16/459,006
Granted
Mar 11, 2025
Kind
B2
Abstract

Methods for alleviating one or more symptoms and/or inhibiting muscle disuse atrophy in mammals via administration of compositions of egg powder protein are provided.

Claims (9)

1. A method for inhibiting, reversing and/or alleviating muscle disuse atrophy in a canine following surgery, said method comprising orally administering daily to the canine following surgery a composition comprising an egg yolk derived product in an amount of egg yolk derived product effective to inhibit, reverse and/or alleviate muscle disuse atrophy following surgery in the canine as compared to a canine following surgery and receiving a placebo.

2. The method of claim 1 wherein the composition comprises a fertilized egg yolk derived product.

3. The method of claim 1 wherein the egg yolk derived product is administered in an amount effective to upregulate mTor pathway activity, downregulate ubiquitin proteasome pathway activity and/or reduce ActRIIB expression.

4. The method of claim 1 wherein the composition comprises avian follistatin.

5. The method of claim 1 wherein the composition is administered to the canine prior to and following a surgical procedure.

6. The method of claim 5 wherein the surgical procedure is an orthopedic surgical procedure.

7. The method of claim 1 wherein administration of the composition results in reduced muscle atrophy of disuse, increased muscle thickness, lower reduction in muscle thickness and/or muscle mass, improved muscle function, increased muscle force generation, reduced inflammation and/or reduced recovery time in the canine.

8. The method of claim 1 wherein the composition comprising egg yolk derived product is administered about 1 to about 4 weeks before surgery and is continued for about 6 to 12 weeks post surgery.

9. The method of claim 1 wherein the composition comprising egg yolk derived product is administered orally on a daily basis in an amount ranging from about 200-1000 mg/kg/day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2022
From: MYOS RENS TECHNOLOGY INC.
To: MYOS CORP.
Reel/Frame 059426/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2019
From: MANNELLO, JOSEPH; PADLIYA, NEERAV; DARIANI, MAGHSOUD
To: MYOS RENS TECHNOLOGY INC.
Reel/Frame 049843/0210 →
Continuity (4)
Provisional Application 62790612 · Jan 10, 2019
Provisional Application 62756279 · Nov 6, 2018
Provisional Application 62724263 · Aug 29, 2018
Related Publication 20200069742A1 · Mar 5, 2020
References Cited (30)
US 20070275036A1 · Green Iii · 2007 [cited by applicant]
US 20150238566A1 · Padliya · 2015 [cited by examiner]
US 20170196944A1 · Portman · 2017 [cited by examiner]
EP 2674033 · 2013 [cited by applicant]
JP 2017513882A1 · 2017 [cited by examiner]
WO 2015187977 · 2015 [cited by applicant]
Protein Factory 2016, https://proteinfactory.com/myostatin-supplement/. [cited by examiner]
Carroza 2018 https://www.dvm360.com/view/new-supplement-addresses-muscle-atrophy-in-dogs (Year: 2018). [cited by examiner]
Rogers, 2016 https://proteinfactory.com/myostatin-supplement/. [cited by examiner]
Adams et al. “Influence of signalment on developing cranial cruciate rupture in dogs in the UK” Journal of Small Animal Practice 2011 52(7) :347-352. [cited by applicant]
Baird et al. “Genome-wide association study identifies genomic regions of association for cruciate ligament rupture in Newfoundland dogs” Animal Genetics 2014 45 (4) :542-549. [cited by applicant]
Benabdallah et al. “Overexpression of follistatin in human myoblasts increases their proliferation and differentiation, and improves the graft success in SCID mice” Cell Transplantation 2009 18:709-718. [cited by applicant]
Chang et al. “The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs” Transgenic Res. 2017 26:25-36. [cited by applicant]
Freeman et al. “Arthrogenic neuromusculature inhibition: a foundational investigation of existence in the hip joint” Clinical Biomechanics 2013 28(2) :171-177. [cited by applicant]
Goldspink et al. “The effect of hypokinesia and hypodynamia on protein turnover and the growth of four skeletal muscles of the rat” Pflügers Archiv 1986 407(3) :333-340. [cited by applicant]
Guerrero et al. “Effect of conformation of the distal portion of the femur and proximal portion of the tibia on the pathogenesis of cranial cruciate ligament disease in dogs” American Journal of Veterinary Research 2007… [cited by applicant]
Holm et al. “Surgery-induced changes and early recovery of hip-muscle strength, leg-press power, and functional performance after fast-track total hip arthroplasty: a prospective cohort study” PloS One 2013 8 (4) :e6210… [cited by applicant]
Holstege et al. “Preoperative quadriceps strength as a predictor for short-term functional outcome after total hip replacement” Archives of Physical Medicine and Rehabilitation 2011 92(2) :236-241. [cited by applicant]
Jackman, R W. and Kandarian, S.C. “The molecular basis of skeletal muscle atrophy” American Journal of Physiology—Cell Physiology 2004 287 (4) :C834-C843. [cited by applicant]
Jensen et al. “Recovery in mechanical muscle strength following resurfacing vs standard total hip arthroplasty—a randomised clinical trial” Osteoarthritis and Cartilage 2011 19(9) :1108-1116. [cited by applicant]
Lemburg et al. “Immunohistochemical characterization of inflammatory cell populations and adhesion molecule expression in synovial membranes from dogs with spontaneous cranial cruciate ligament rupture” Veterinary Immun… [cited by applicant]
Light et al. “Sex hormone regulation of collagen concentrations in cranial cruciate ligaments of sexually immature male rabbits” American Journal of Veterinary Research 2012 73(8) :1186-1193 (Abstract Only). [cited by applicant]
Mizner et al. “Early quadriceps strength loss after total knee arthroplasty. The contributions of muscle atrophy and failure of voluntary muscle activation” The Journal of Bone and Joint Surgery 2005 87(5) :1047. [cited by applicant]
Monk et al. “Effects of early intensive postoperative physiotherapy on limb function after tibial plateau leveling osteotomy in dogs with deficiency of the cranial cruciate ligament” American Journal of Veterinary Resea… [cited by applicant]
Rice, D. A. and McNair P.J. Seminars in Arthritis and Rheumatism. vol. 40. No. 3. WB Saunders, 2010. [cited by applicant]
Sharp et al. “The Effects of Fortetropin Supplementation on Body Composition, Strength and Power in Humans and Mechanism of Action in a Rodent Model” Journal of American College of Nutrition 2016 1-13. [cited by applicant]
Wilson et al. “The Effects of Fertilized Egg Yolk Isolates on Anabolic and Catabolic Signaling in Skeletal Muscle” FASEB Journal 2015 1(15) :819. [cited by applicant]
Yaden et al. “Follistatin: a novel therapeutic for the improvement of muscle regeneration” J. Pharmacol Exp Ther 2014 349:355-371. [cited by applicant]
International Search Report and Written Opinion in PCT/US2019/040103 dated Oct. 11, 2019. [cited by applicant]
White et al. “Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy” PLOS ONE 2020 15 (4) pp. 1-10. [cited by applicant]